Roth Capital raised the firm’s price target on OptimizeRx (OPRX) to $22 from $16 and keeps a Buy rating on the shares. The company reported strong Q1 results, with revenues and adjusted EBITDA both well above estimates marking a good start in its weakest seasonal quarter, the analyst tells investors in a research note. With net dollar retention of 114% essentially accounting for the firm’s 2025 revenue growth forecast of 14%, the company’s increased 2025 revenue and EBITDA guidance still look conservative, Roth adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP
- OptimizeRx Reports Strong Q1 2025 Financial Growth
- OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition
- OptimizeRx reports Q1 non-GAAP EPS 8c, consensus (12c)